Company: GVH
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046965
Chunk: 44

Company: Globavend Holdings Ltd
Filing Date: 2025-05-23
Form: F-1
Chunk 44
---
 “Low Priced Stock Rule”) provides that if a company’s security has a closing bid price of $0.10 or less for ten consecutive trading days during any bid price compliance period, Nasdaq must issue a delisting determination with respect to that security. The closing price of our Ordinary Shares on Nasdaq on May19, 2025 was $1.36 per share. A sale of substantial number of Ordinary Shares could depress the trading price of our Ordinary Shares and result in non -complianceof the Low Priced Stock Rule. If we receive a letter from Nasdaq indicating that we are not compliant with the Low Priced Stock Rule, we may timely request a hearing before a Hearings Panel to appeal the delisting determination, which would stay the delisting and suspension of our Ordinary Shares pending the decision of the Hearings Panel. No assurances may be made as to whether our effectuation of a reverse stock would cure any future deficiencies regarding the price of our Ordinary Shares for purposes of the Low Priced Stock Rule. This offering may result in an immediate trading halt or delisting of our Ordinary Shares from The Nasdaq Capital Market due to public interest concerns. Under Nasdaq Listing Rule 5101, The Nasdaq Stock Market has broad discretionary authority to terminate the listing of securities, subject to a timely -requestedhearing, if it determines that continued listing is not in the public interest, even if the issuer is in compliance with The Nasdaq Stock Market’s enumerated listing criteria. The Series A Warrants and Series B Warrants contain exercise price reset provisions that may result in a downward adjustment 14 to the exercise price, subject to a floor price. As a result of such features, the price of our Ordinary Shares issuable upon exercise of the Series A Warrants and Series B warrants may be substantially below the then existing market price. Further, if the holders of the Series B Warrants elect the “zero exercise price” option, the maximum number of Ordinary Shares issuable upon exercise of the Series B Warrants will equal to the product of (a) the number of shares that would be issuable upon exercise of the Series B Warrant in accordance with the terms of such warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (b) the quotient obtained by dividing (i) the exercise price minus the Low Price by (ii) 50% of the Low Price, resulting in a maximum of 242,647,065 Ordinary Shares issuable upon the exercise of